Autoantibodies to factor H (FH), the major soluble regulatory protein of the alternative complement pathway, are described in kidney diseases such as atypical hemolytic uremic syndrome (aHUS) and dense deposit disease, and are thought to cause pathogenic complement activation by blocking functional domains of this complement inhibitor protein (14, 32–34). This evidence concerns the gene FH and dense deposit disease.